Details of the Drug Pharmacogenomic Perturbation Atlas
General Information of Drug (ID: DM26SE7)
| Drug Name | ||||||
|---|---|---|---|---|---|---|
| Synonyms |
CHEMBL16410; UNII-929J96FO8T; 82668-33-5; JPC-211; U-99194A maleate; 929J96FO8T; PNU-99194A free base; 5,6-dimethoxy-n,n-dipropylindan-2-amine; JPC 211; Tocris-1357; NCGC00016073-01; 2-Di-n-propylamino-5,6-dimethoxyindane; Lopac-U-116; 1H-Inden-2-amine, 2,3-dihydro-5,6-dimethoxy-N,N-dipropyl-; AC1L1KRQ; Biomol-NT_000031; AC1Q56MX; Lopac0_001207; ZINC7459; SCHEMBL2640137; BPBio1_001223; CHEBI:93232; DTXSID50274471; BDBM50107876; CCG-205281; PNU-99,194; API0008965; NCGC00025123-03; NCGC00025123-01; NCGC00016073-02
| |||||
| Cross-matching ID | ||||||
Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
|
|
||||||||||||||||||||||||||
|
||||||||||||||||||||||||||
Pharmacogenomic Perturbation Across Diseases and Tissues
|
Bone
Osteosarcoma
Breast
Breast adenocarcinoma
Colon
Colorectal adenocarcinoma
Hematopoietic system
Normal
Kidney
Normal (Immortalized)
Liver
Hepatoblastoma
Lung
Lung adenocarcinoma
Non-small cell lung carcinoma
Prostate
Prostate carcinoma
Skin
Melanoma
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
